The following provides specific information in relation to the Challenger Guaranteed Pension Fund (ARSN 154 366 588) (Fund) issued by Challenger Retirement and Investment Services Limited (ABN 80 115 534 453) (AFSL 295642) offered in the Product Disclosure Statement (PDS) dated 1 Jul 2019 .
We recommend that you read the below information in conjunction with the PDS before making an investment decision. The information contained below is current and will be updated when we issue a new class of unit or close an existing class of unit. Any future updates will be available on this website. A paper copy of the below information will be given to you, without charge, on request by calling our Investor Services team on 13 35 66.
Open classes
| Class name |
Commencement date |
Distribution amount |
Indexation date |
Indexation amount |
Maturity date |
Maturity per unit |
|---|---|---|---|---|---|---|
| CGPF 31 December 2023 |
10 December 2018 |
$1.0000 |
N/A |
0 |
31 December 2023 |
Nil |
Closed classes
| Class name |
Commencement date |
Distribution amount |
Indexation date |
Indexation amount |
Maturity date |
Maturity per unit |
|---|---|---|---|---|---|---|
| CGPF (I) 30 June 2021 |
7 December 2011 |
$1.0000 |
1 July each year |
3.00% (fixed) |
30 June 2021 |
Nil |
Dated 1 January 2020. Issued by Challenger Retirement and Investment Services Limited (ABN 80 115 534 453) (AFSL 295642). In preparing the information contained above we did not take into account your particular investment objectives, financial situation or needs. As investors' needs and aspirations differ, you should consider the applicable PDS and whether investing in these Funds is appropriate for you in light of your particular needs, objectives and financial circumstances. You may also wish to obtain independent advice, particularly about individual matters such as taxation, retirement planning and investment risk tolerance. The guarantees to the Fund provided by Challenger Life Company Limited are referrable to its Statutory Fund No.2. and are explained in the PDS.